In Setback for Glaxo, U.K. Invalidates Paxil Patent

Law360, New York (October 31, 2005, 12:00 AM EST) -- The U.K. House of Lords has upheld a lower court’s decision to invalidate the patent for the key ingredient in GlaxoSmithKline’s Paxil, one of the world’s most widely prescribed antidepressants.

The Lords ruled in late October that Glaxo’s patent for the compound paroxetine mesylate was invalid and upheld an appeal brought by challenger Synthon against the decision of the Court of Appeal, which was made in June 2003. Paroxetine mesylate incorporates the main ingredient of Paxil, one of Glaxo’s best selling drugs.

Synthon challenged the validity...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.